A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Latest Information Update: 07 Apr 2026
At a glance
- Drugs Admilparant (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ALOFT; ALOFT-IPF
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 24 Mar 2026 Planned End Date changed from 26 Oct 2026 to 4 Jun 2027.
- 24 Mar 2026 Planned primary completion date changed from 26 Oct 2026 to 6 Oct 2026.
- 15 Sep 2025 Status changed from recruiting to active, no longer recruiting.